NASDAQ: MNOV - MediciNova, Inc.

Yield per half year: +47.86%
Sector: Healthcare

Share chart MediciNova, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.

more details
The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.014
EV/EBITDA -15.9
IPO date 2005-02-08
ISIN US58468P2065
Industry Biotechnology
P/BV 3.82
P/S 58.4
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.004
Сайт https://www.medicinova.com
Цена ао 1.36
Число акций ао 0.04905 млрд
Change price per day: +6.15% (1.95)
Change price per week: -4.61% (2.17)
Change price per month: +2.99% (2.01)
Change price per 3 month: +8.38% (1.91)
Change price per half year: +47.86% (1.4)
Change price per year: +38% (1.5)
Change price per 3 year: -24.45% (2.74)
Change price per 5 year: -71.68% (7.31)
Change price per 10 year: 0% (2.07)
Change price per year to date: -2.82% (2.13)
All parameters

Underestimation

Title Value Grade
P/S 71.61 1
P/BV 1.15 9
P/E 0 0
EV/EBITDA -2.11 0
Total: 4.63

Efficiency

Title Value Grade
ROA, % -12.93 0
ROE, % -13.74 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0219 10
Total: 6.2

Growth impulse

Title Value Grade
Yield Revenue, % 24.6 4
Yield Ebitda, % -29.43 0
Yield EPS, % -41.73 0
Total: 0.8
More

Institutions Volume Share, %
Essex Woodlands Management Inc. 1105941 2.25
Blackrock Inc. 699642 1.43
Vanguard Group Inc 623333 1.27
Citigroup Inc. 447957 0.91
Geode Capital Management, LLC 435733 0.89
Renaissance Technologies, LLC 174100 0.35
Bank of America Corporation 167959 0.34
State Street Corporation 157198 0.32
Northern Trust Corporation 153556 0.31
Dimensional Fund Advisors LP 152530 0.31

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.02281 13.79 1.54048



Head Job title Payment Year of birth
Dr. Yuichi Iwaki M.D., Ph.D. Co-Founder, President, CEO & Executive Director 907.26k 1950 (75 years)
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. Chief Medical Officer & Director 649.05k 1966 (59 years)
Mr. Jason J. Kruger CPA CFO & Principal Financial Officer N/A 1978 (47 years)
Dr. David H. Crean M.B.A., Ph.D. Chief Business Officer N/A 1965 (60 years)
Mr. John O'Neil CPA Controller

Address: United States, La Jolla. CA, 4275 Executive Square - open in Google maps, open in Yandex maps
Website: https://www.medicinova.com